- Home
- MFH vs MNPR Comparison
MFH vs MNPR Comparison
Compare MFH & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFH
- MNPR
- Stock Information
- Founded
- MFH 2011
- MNPR 2014
- Country
- MFH United States
- MNPR United States
- Employees
- MFH N/A
- MNPR N/A
- Industry
- MFH Finance: Consumer Services
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- MFH Finance
- MNPR Health Care
- Exchange
- MFH Nasdaq
- MNPR Nasdaq
- Market Cap
- MFH 249.7M
- MNPR 248.8M
- IPO Year
- MFH N/A
- MNPR 2019
- Fundamental
- Price
- MFH $4.30
- MNPR $35.71
- Analyst Decision
- MFH
- MNPR Strong Buy
- Analyst Count
- MFH 0
- MNPR 7
- Target Price
- MFH N/A
- MNPR $62.00
- AVG Volume (30 Days)
- MFH 1.7M
- MNPR 20.7K
- Earning Date
- MFH 08-26-2025
- MNPR 08-12-2025
- Dividend Yield
- MFH N/A
- MNPR N/A
- EPS Growth
- MFH N/A
- MNPR N/A
- EPS
- MFH N/A
- MNPR N/A
- Revenue
- MFH N/A
- MNPR N/A
- Revenue This Year
- MFH N/A
- MNPR N/A
- Revenue Next Year
- MFH N/A
- MNPR N/A
- P/E Ratio
- MFH N/A
- MNPR N/A
- Revenue Growth
- MFH 125.92
- MNPR N/A
- 52 Week Low
- MFH $1.03
- MNPR $2.15
- 52 Week High
- MFH $8.86
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- MFH 56.20
- MNPR 43.81
- Support Level
- MFH $3.72
- MNPR $30.51
- Resistance Level
- MFH $4.45
- MNPR $36.51
- Average True Range (ATR)
- MFH 0.52
- MNPR 3.33
- MACD
- MFH 0.07
- MNPR -0.95
- Stochastic Oscillator
- MFH 57.14
- MNPR 37.55
About MFH Mercurity Fintech Holding Inc.
Mercurity Fintech Holding Inc is a New York-based digital fintech leader providing access to the rapidly growing AI-powered infrastructure, blockchain, and digital assets sectors. Its three core business lines include: 1. Blockchain and digital asset solutions. 2. AI and HPC infrastructure, specializing in developing liquid cooling solutions for AI data centers. 3. Comprehensive financial services.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.